Press Release

View printer-friendly version Back

Lantheus Medical Imaging to Present at Upcoming Investor Conferences

N. Billerica, Mass., February 21, 2012Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that the Company will be participating in the following investor conferences:

Citi 2012 Global Health Care Conference
Monday, February 27 at 3:30 p.m. EST

2012 RBC Capital Markets’ Healthcare Conference
Tuesday, February 28 at 8:00 a.m. EST

Don Kiepert, President and Chief Executive Officer, will present an overview of the Company and its product pipeline at each conference.

A live webcast of each presentation will be available on the homepage of the Company’s website at www.lantheus.com.  A replay of the webcasts will be available on the Company’s website for two weeks following the presentations.

About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.